Accurate diagnosis of LMNA::NTRK1-rearranged neoplasms is clinically critical due to the availability of TRK inhibitors, which achieve response rates exceeding 75% in NTRK fusion-positive solid tumors (2, 28). The gene discussed is NTRK1; the disease is neoplasm.